April 16, 2023: Durvalumab (IV) / NSCLC / AstraZeneca: Results from Phase 3 AEGEAN study demonstrated prolong event-free survival
AstraZeneca reported data from AACR 2023 for Phase 3 AEGEAN trial evaluating Neoadjuvant Durvalumab plus Chemotherapy followed by Adjuvant Durvalumab in patients with NSCLC
Durvalumab regimen led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) and pathologic complete response (pCR)
info@ciscientists.com
For a subscription, please provide your email id